Argent BioPharma

31 July 2026

Argent BioPharma Expands CannEpil® Global Licence into Veterinary Healthcare

Highlights:

- **Global CannEpil® licensing agreement expanded to include veterinary applications alongside human neurological indications.**
- **Existing 15% perpetual royalty for human therapeutic applications remains unchanged.**
- **New veterinary indication established under a 10% perpetual royalty structure, creating an additional long-term revenue stream.**
- **Splash Beverage Group intends to collaborate with Lupvindol UK Limited to advance CannEpil® through the U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM) regulatory pathway.**
- **Veterinary programme expected to pursue the Investigational New Animal Drug (INAD) and Conditional Approval pathways in the United States.**
- **Argent BioPharma retains ownership of all existing and future CannEpil® intellectual property, manufacturing know-how and regulatory assets.**

Veterinary Market Expansion Creates Second Commercial Opportunity.

Argent BioPharma Ltd (**ASX: RGT**) (**Argent** or the **Company**) is pleased to announce that it has executed **Addendum No. 1** to its recently announced Exclusive Global Licensing Agreement for CannEpil®, expanding the commercial scope of the agreement to include veterinary applications and establishing a dedicated pathway for development within the global animal health market.

The amendment broadens the licensed field beyond human neurological indications to include veterinary applications, creating a second commercial opportunity for CannEpil® and significantly expanding the product's long-term addressable market.

Under the revised commercial framework, Argent BioPharma **retains its existing 15% perpetual royalty** on future human therapeutic sales of CannEpil®. The amendment also introduces a **10% perpetual royalty** for veterinary applications, reflecting the inclusion of a specialist veterinary development partner and the establishment of a separate commercial and regulatory pathway for the animal health market.

The veterinary royalty represents a new revenue stream that did not exist under the original agreement and enables the commercialisation of CannEpil® across an additional healthcare sector while preserving Argent's participation in future product revenues.

U.S. Veterinary Development Programme

As part of the amended agreement, Splash Beverage Group has advised Argent BioPharma of its intention to enter into a development and collaboration agreement with **Lupvindol UK Limited** to advance CannEpil® through the **U.S. Food and Drug Administration Center for Veterinary Medicine (FDA CVM)**.

Lupvindol UK Limited will collaborate with Splash Beverage Group on the veterinary development programme, supporting the advancement of CannEpil® through the FDA's **Investigational New Animal Drug (INAD)** and **Conditional Approval** pathways. This establishes a defined regulatory strategy for entry into the U.S. veterinary pharmaceutical market.

Argent BioPharma has consented to the limited use of its intellectual property solely for the purposes of this veterinary development programme. Splash Beverage Group remains fully responsible for all obligations under the Exclusive Licensing Agreement, and Argent BioPharma continues to retain ownership of all existing and future CannEpil® intellectual property, manufacturing know-how, regulatory assets and future development rights.

Preserving Long-Term Shareholder Value

The amendment does not alter Argent BioPharma's ownership of CannEpil®. The Company continues to retain ownership of all existing and future intellectual property, manufacturing know-how and regulatory assets associated with the product.

Argent BioPharma will also continue to manufacture CannEpil® through its EU-GMP manufacturing network, preserving future manufacturing revenues while participating in long-term commercial success through royalties across both the human and veterinary healthcare markets.

Strategic Rationale

The Board believes the amendment materially strengthens the original licensing transaction by:

- Expanding CannEpil® into the global veterinary healthcare market.
- Creating a second commercial pathway alongside the existing human therapeutic programme.
- Establishing a dedicated U.S. veterinary regulatory strategy through collaboration with Lupvindol UK Limited.
- Preserving the Company's existing 15% royalty participation for human therapeutic applications.
- Creating an additional 10% perpetual royalty stream from veterinary applications.
- Preserving ownership of all intellectual property, manufacturing know-how and future development rights.
- Strengthening the Company's long-term recurring revenue profile through diversified royalty and manufacturing income.

Roby Zomer, Chairman, commented:

"The original CannEpil® licensing transaction established a strong commercial foundation for the global development of the product. This amendment builds upon that foundation by expanding CannEpil® into the veterinary healthcare market while preserving Argent's long-term participation in both human and animal health applications.
We are particularly encouraged that our licensing partner has already initiated plans to collaborate with Lupvindol UK Limited to pursue the FDA's veterinary approval pathway. This demonstrates early execution of the commercial strategy and establishes a clear regulatory roadmap for entry into the U.S. animal health market.
Importantly, Argent continues to retain ownership of all CannEpil® intellectual property, manufacturing capabilities and future development rights. Together with our ongoing royalty participation across both human and veterinary markets, this amendment further strengthens the long-term value proposition of the CannEpil® platform for our shareholders."

About CannEpil®

CannEpil® is a pharmaceutical-grade cannabinoid combination therapy formulated as a standardised 20:1 CBD:THC oral solution and developed for the management of drug-resistant epilepsy, also referred to as refractory epilepsy. Drug-resistant epilepsy affects approximately one-third of all epilepsy patients worldwide and remains one of the largest unmet needs in neurology.

The product has established regulatory and commercial access pathways across multiple jurisdictions, including Ireland, the United Kingdom, Germany, and Australia. CannEpil® is supported by real-world clinical evidence, peer-reviewed publications, EU-GMP manufacturing infrastructure, and an active FDA IND programme in the United States.

CannEpil® has achieved full reimbursement status in Ireland under the Medicinal Cannabis Access Programme and recently completed the largest commercial shipment in the product's history, with 1,000 units delivered into the Irish market.

The Company believes CannEpil® represents a differentiated cannabinoid therapy opportunity within the global drug-resistant epilepsy market, supported by an established clinical and commercial foundation and a defined regulatory pathway toward further development in major pharmaceutical markets.

—Ends—

Authorised for release by the Chairman, for further information please contact:

Argent BioPharma
Roby Zomer
Chairman
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma

About Argent BioPharma

Argent BioPharma Ltd. (ASX: RGT) is a revenue-generating specialty biopharmaceutical company focused on building a differentiated **immune-modulation intellectual property platform** through the development, commercialisation and strategic licensing of innovative therapeutics.

The Company's portfolio is anchored by **CimetrA®**, a first-in-class immune-modulating platform targeting inflammatory and autoimmune diseases, supported by proprietary **NanoBodies™ and peptide technologies**, advanced nano-delivery systems and EU-GMP manufacturing capabilities.

Following the global licensing of **CannEpil®**, Argent BioPharma has adopted a capital-efficient strategy that combines proprietary intellectual property, commercial-stage products, strategic licensing, manufacturing services and recurring royalty income to create long-term shareholder value.

With a focused pipeline of immune-modulating technologies, a growing portfolio of proprietary pharmaceutical assets and an expanding commercial platform, Argent BioPharma is positioning itself as a next-generation specialty pharmaceutical company with a clear pathway toward expansion into the United States capital markets.

About Splash Beverage Group, Inc. (NYSE American: SBEV)

Splash Beverage Group, Inc. (NYSE American: SBEV) is a publicly traded company headquartered in Fort Lauderdale, Florida. The Company is pursuing a strategic transformation toward becoming a cannabinoid health, wellness, and biopharmaceutical platform through disciplined capital allocation, strategic investments, acquisitions, and other platform-building initiatives.

Argent BioPharma ltd
Suite 1, 295 Rokeby Road
Subiaco, WA 6008, Australia

+61 8 6555 2950

info@argentbiopharma.com